Cue Biopharma

Update in progress

CUE (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Cue Biopharma, Inc. is a Boston-based clinical-stage biopharmaceutical company developing injectable therapies that selectively modulate disease-relevant T cells. Lead programs include CUE-401, a preclinical bifunctional fusion protein to promote immune tolerance by converting Teff cells to iTregs; CUE-501, a preclinical approach to deplete B cells via antiviral T cell–mediated mechanisms. CUE-101 is in Phase 1b for HPV+ recurrent/metastatic head and neck cancer, including combinations with KEYTRUDA; CUE-102 is in Phase 1b for WT1+ colorectal, gastric, ovarian, and pancreatic cancers. Uses collaborations with LG Chem and Ono, and Einstein College of Medicine. Formerly Imagen Biopharma, renamed Cue Biopharma in 2016. Incorporated 2014.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive